Immunologix, Inc., Charleston, S.C., and DavosPharma, Upper Saddle River, N.J. have formed a strategic alliance whereby DavosPharma, a provider of discovery, chemistry, and formulation services, will represent and market 100% human antibodies produced by Immunologix.
Immunologix transforms naïve B-cells to produce 100% human monoclonal antibodies that can target any and all antigens including, cancer, viruses, bacteria, toxins and auto-immune diseases like diabetes, lupus, rheumatoid arthritis and multiple sclerosis. Immunologix collects patient-consented explanted tonsil tissue following tonsillectomies and processes them in its laboratory.
The company holds a worldwide exclusive license from the Medical University of South Carolina, and exclusive U.S. and foreign patents in this technological platform.
“The relationship between Immunologix and DavosPharma has been building since initial discussions began in December of 2010. We are extremely excited to partner with DavosPharma since they bring an experienced team of experts to Immunologix.
Together, the companies will offer customers complete transparency. The partnership allows both parties to offer their clients a platform to 100% human monoclonal antibody ready for clinical trials. It will help in bringing our game changing technology to the pharmaceutical marketplace,” said Dr. Ryan Fiorini. “This agreement is a win-win for both companies and we are happy to team up with DavosPharma to expand our capabilities.”
Barry Robins emphasized, “The Immunologix platform of technology offers a new paradigm for therapeutic antibody discovery, development, and manufacturing. Our customers will understand that the ability to identify and produce a 100% human monoclonal antibody in less than 6 months with less adverse side effects is an extremely significant differentiator. The technology that we now offer through this strategic alliance will have an immediate impact on shorter development times, costs, and reduction of adverse effects due to immunogenicity which often derail therapeutic antibody programs. Many of our existing clients will be very interested in adopting this technology.”